cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Portage Biotech Inc
1 own
1 watching
Current Price
$4.63
$0.08
(1.76%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
78.46M
52-Week High
52-Week High
11.99
52-Week Low
52-Week Low
4.11
Average Volume
Average Volume
0.03M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization78.46M
icon52-Week High11.99
icon52-Week Low4.11
iconAverage Volume0.03M
iconDividend Yield--
iconP/E Ratio--
What does the Portage Biotech Inc do?
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company s product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
Read More
News & Events about Portage Biotech Inc.
Globe Newswire
3 months ago
Updated data support the proof of concept of using an iNKT agonist monotherapy (PORT-2) to induce immune response for patients with refractory NSCLC and melanomaWESTPORT, Conn., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing...
Globe Newswire
3 months ago
Study will evaluate PORT-2 in combination with KEYTRUDA (pembrolizumab) for the treatment of patients with front-line as well as refractory non-small cell lung cancer (NSCLC)WESTPORT, Conn., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc., (NASDAQ: PRTG) (Portage or the Company), a clinical-...
Globe Newswire
5 months ago
--Robust Pipeline Now Includes Five Clinical-Stage Small Molecule Immuno-Oncology Assets, Including Invariant Natural Killer T Cell (iNKT) Agonists and Adenosine Antagonists-- ---Cash Runway for New and Current Programs Potentially Extended into 2024-- WESTPORT, Conn., Aug. 29, 2022 (GLOBE NEWSWIRE...
Globe Newswire
6 months ago
--Company Continues to Execute on Core Business Model While Enhancing Value Proposition and Pipeline with Recent Transactions-- --Robust Pipeline Now Includes Four Fully Owned, Clinical-Stage Assets-- --Cash Runway for New and Current Programs Potentially Extended into 2024-- WESTPORT, Conn., Aug. ...
Globe Newswire
6 months ago
Portage now holds 100% ownership of iOx Therapeutics Ltd., buying out remainder of equity in exchange for PRTG stockWESTPORT, Conn., July 20, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and ...
Frequently Asked Questions
Frequently Asked Questions
What is Portage Biotech Inc share price today?
plus_minus_icon
Can Indians buy Portage Biotech Inc shares?
plus_minus_icon
How can I buy Portage Biotech Inc shares from India?
plus_minus_icon
Can Fractional shares of Portage Biotech Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Portage Biotech Inc stocks?
plus_minus_icon
What is today’s traded volume of Portage Biotech Inc?
plus_minus_icon
What is today’s market capitalisation of Portage Biotech Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Portage Biotech Inc?
plus_minus_icon
What percentage is Portage Biotech Inc down from its 52-Week High?
plus_minus_icon
What percentage is Portage Biotech Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$4.63
$0.08
(1.76%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00